EP1232247A4 - Modulation de transduction de signal - Google Patents

Modulation de transduction de signal

Info

Publication number
EP1232247A4
EP1232247A4 EP00991029A EP00991029A EP1232247A4 EP 1232247 A4 EP1232247 A4 EP 1232247A4 EP 00991029 A EP00991029 A EP 00991029A EP 00991029 A EP00991029 A EP 00991029A EP 1232247 A4 EP1232247 A4 EP 1232247A4
Authority
EP
European Patent Office
Prior art keywords
modulation
signal transduction
transduction
signal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00991029A
Other languages
German (de)
English (en)
Other versions
EP1232247A2 (fr
Inventor
Gerhart Graupner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Graupner Gerhart
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1232247A2 publication Critical patent/EP1232247A2/fr
Publication of EP1232247A4 publication Critical patent/EP1232247A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
EP00991029A 1999-11-23 2000-11-22 Modulation de transduction de signal Withdrawn EP1232247A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16743899P 1999-11-23 1999-11-23
US167438P 1999-11-23
PCT/US2000/042233 WO2001038344A2 (fr) 1999-11-23 2000-11-22 Modulation de transduction de signal

Publications (2)

Publication Number Publication Date
EP1232247A2 EP1232247A2 (fr) 2002-08-21
EP1232247A4 true EP1232247A4 (fr) 2003-06-18

Family

ID=22607380

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00991029A Withdrawn EP1232247A4 (fr) 1999-11-23 2000-11-22 Modulation de transduction de signal

Country Status (5)

Country Link
EP (1) EP1232247A4 (fr)
JP (1) JP2003518017A (fr)
AU (1) AU3082901A (fr)
CA (1) CA2392453C (fr)
WO (1) WO2001038344A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1768657T1 (sl) 2004-06-23 2009-02-28 Sirion Terapeutics Inc Postopki in sestavki za zdravljenje oftalmičnih obolenj z derivati retinila
WO2006052860A2 (fr) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulateurs de la formation d'un complexe transthyretine (ttr)-proteine de liaison retinol-retinol (rbp)
CN101072555B (zh) * 2004-12-08 2011-06-29 矫正诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO0138344A3 *
SUCOV H M ET AL: "RETINOIC ACID AND RETINOIC ACID RECEPTORS IN DEVELOPMENT", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, vol. 10, no. 2/3, 1995, pages 169 - 184, XP002949771, ISSN: 0893-7648 *

Also Published As

Publication number Publication date
WO2001038344A3 (fr) 2002-01-10
CA2392453C (fr) 2012-03-20
CA2392453A1 (fr) 2001-05-31
JP2003518017A (ja) 2003-06-03
AU3082901A (en) 2001-06-04
WO2001038344A2 (fr) 2001-05-31
EP1232247A2 (fr) 2002-08-21

Similar Documents

Publication Publication Date Title
AU3529800A (en) Antisense modulation of interleukin-5 signal transduction
AU6296199A (en) Antisense modulation of smad1 expression
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
EP1206478A4 (fr) Composes antisens modulant l'expression de mekk5
AU5486400A (en) Mixed signal synthesis
EP1248611A4 (fr) Inhibition de systemes de transduction de signal possedant deux composantes
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
GB9903114D0 (en) Signal transmission
EP1218407A4 (fr) Utilisation de la kappa-conotoxine pviia
EP1232247A4 (fr) Modulation de transduction de signal
GB2353037B (en) Modification of polymers
AU1489701A (en) Antisense modulation of nck-2 expression
AU5615700A (en) Antisense modulation of g-alpha-i2 expression
PL350963A1 (en) Use of arylalkanoylpyridazines
AU1221101A (en) Antisense modulation of cytohesin-2expression
GB0011407D0 (en) Synthesis of substituted prolines
EP1196425A4 (fr) Detection de giardia
GB2348761B (en) Signal generator
GB2348763B (en) Signal generator
GB0015131D0 (en) Signal modulation
GB9906591D0 (en) Signal lineariser
EP1146707A4 (fr) Generateur de signaux de modulation numeriques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020617

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030506

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/203 B

Ipc: 7C 12N 5/06 A

Ipc: 7A 61K 31/07 B

17Q First examination report despatched

Effective date: 20080716

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GRAUPNER, GERHART

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRAUPNER, GERHART

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130601